Please assess the completion status of the following clinical trial:

Trial Title: Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age less than 30 days of age at time of surgery with need for cardiopulmonary bypass with cardioplegic arrest (with or without deep hypothermic circulatory arrest)~* Diagnosis with cyanosis at baseline (pre-operative PaO2 of less than 50mmHG) due to:~  * Complete admixture lesion (example: hypoplastic left heart syndrome, total anomalous pulmonary venous return, truncus arteriosus, pulmonary atresia with VSD)~ * Transposition physiology (example: D-Transposition of the great arteries or Double outlet right ventricle with subpulmonary VSD)~ * Right-to-left shunt (example: Tetralogy of Fallot, double outlet right ventricle with subaortic VSD and pulmonary stenosis)~Exclusion Criteria:~* Corrected gestation at time of surgery less than 37 weeks~* Prior cardiac arrest~* Current or prior history of extracorporeal membrane oxygenation (ECMO) support~* Current or prior history of needing renal replacement therapy with dialysis~* Prior cardiac surgery requiring cardiopulmonary bypass~* Diagnosis of Ebstein's Anomaly~* Known genetic syndrome other than Trisomy 21 or DiGeorge Syndrome

- Gender: ALL
- Minimum Age: None
- Maximum Age: 29 Days
- Healthy Volunteers: f

Study Arms:
- Normoxia (Type: EXPERIMENTAL): On bypass, goal PaO2 on cardiopulmonary bypass of 60-100 mm Hg using lower fraction of inspired oxygen (FiO2) (blended sweep gas) via oxygenator~Post-bypass, goal of PaO2 \<100 mm Hg by anesthesia and in ICU via oxygen titration via mechanical ventilator for 24 hours post-op.
- Standard of care (Type: ACTIVE_COMPARATOR): Frequent blood gases will be checked per protocol on bypass and correlated with the blood parameter monitoring system to maintain a PaO2 of 200-300 per standard practice

Based on this trial design, predict the completion outcome and termination type (if applicable).